News
The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback